Features | Partner Sites | Information | LinkXpress
Sign In
Advantech Europe
VIEWORKS
Primedic

Blood Test Measures Hodgkin’s Chemotherapy Success

By HospiMedica International staff writers
Posted on 06 Mar 2013
A cheap and easy to use diagnostic test helps determine the success of chemotherapy in patients enduring Hodgkin’s lymphoma (HL).

Researchers at the Queensland Institute of Medical Research (QIMR; Brisbane, Australia), the University of Melbourne (Australia), and other institutions prospectively measured serum CD163 (sCD163) and the Hodgkin-Reed-Sternberg (HRS)-specific serum protein sTARC in 221 samples taken from 47 patients with HL, and 21 healthy participants. Blood was drawn at five fixed time-points prior, during, and after first-line therapy. The results were compared with radiological assessment and plasma Epstein-Barr virus DNA (EBV-DNA). The researchers also examined potential sources of circulating CD163, as well as immunosuppressive properties of CD163.

The results showed that prior to therapy, both sCD163 and sTARC were markedly elevated compared with healthy and complete remission samples; sCD163 better reflected tumor burden during therapy, and sTARC presenting greater value upon completion of therapy. Additionally, sCD163 correlated with plasma EBV-DNA, and was associated with B symptoms, stage, and lymphopenia. The researchers found that the combination of both proteins was more informative as a disease response biomarker than either marker alone, in early and advanced disease during first-line therapy for classical HL. The study was published in the February 2013 issue of Clinical Cancer Research.

“This has the potential to be a huge aid for doctors in their decision making and a faster and less invasive process for the patients. Up until now, clinicians have relied on scans to help them judge how well people are responding to chemotherapy,” said lead author Professor Maher Gandhi, PhD, of the QIMR Clinical Immunohaematology Laboratory. “This discovery means we can work towards using simple blood tests to provide quicker, cheaper, and more regular monitoring of how a person is responding to treatment.”

Response biomarkers for classical HL might arise from Hodgkin-Reed-Sternberg (HRS) cells or nonmalignant tumor-infiltrating cells. While HRS cells are sparse within the diseased node, benign CD163(+) M2 tissue-associated macrophages (TAM) are prominent. It is known that CD163(+) cells within the malignant node may be prognostic, but until now there has been no data on serum CD163.

Related Links:

Queensland Institute of Medical Research
University of Melbourne



Channels

Women's Health

view channel

Women Undergoing Heart Attack Delay Hospital Arrival

Women suffering a heart attack wait much longer than men to call emergency medical services and face significantly longer delays getting to a hospital, according to a new study. Researchers at the University of Bologna (Italy) examined records of 7,457 European patients enrolled from 2010 to 2014 in an international... Read more

Health IT

view channel
Image: Simulation of color correction using EnChroma Cx (Photo courtesy of EnChroma).

Correcting Glasses Reestablish Indoor Color Vision

Innovative glasses enable red-green color vision deficiency (CVD) sufferers see digital display screens and status indicator lights when performing color-based activities. The EnChroma Cx-65 eyewear... Read more

Business

view channel

Universal Public Drug Coverage Would Save Canada Billions

A new study claims that Canada could save CAD 7.3 billion annually by providing universal public coverage of medically necessary prescription drugs. Researchers at the University of British Columbia (UBC; Vancouver, Canada) and the University of Toronto (ON, Canada) used published data on prescribing patterns and costs... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.